These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26719255)

  • 1. Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.
    Godi A; Facchetti A; Bissett SL; Cocuzza C; Miller E; Beddows S
    J Virol; 2015 Dec; 90(6):3247-52. PubMed ID: 26719255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
    Godi A; Bissett SL; Miller E; Beddows S
    J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
    Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
    J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
    Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Naturally Occurring Variation in the Human Papillomavirus 58 Capsid Proteins on Recognition by Type-Specific Neutralizing Antibodies.
    Godi A; Martinelli M; Haque M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
    J Infect Dis; 2018 Oct; 218(10):1611-1621. PubMed ID: 29905865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
    Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
    Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
    Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
    PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
    Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
    PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles.
    Wang D; Liu X; Wei M; Qian C; Song S; Chen J; Wang Z; Xu Q; Yang Y; He M; Chi X; Huang S; Li T; Kong Z; Zheng Q; Yu H; Wang Y; Zhao Q; Zhang J; Xia N; Gu Y; Li S
    Nat Commun; 2020 Jun; 11(1):2841. PubMed ID: 32503989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells.
    Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP
    Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.
    Bissett SL; Godi A; Beddows S
    Sci Rep; 2016 Dec; 6():39730. PubMed ID: 28004837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.